Banner

IV calcium infusion's role in ovarian hyperstimulation syndrome prevention

• 2022
Back
Publication Information
Authors Mahmoud Ahmed Gehad. MD,
Keywords Not Available
Journal Not Available
Publisher Not Available
Volume Not Available
Issue Not Available
Pages Not Available
publication.type Local
Paper Link Not Available
Supplementary Materials Not Available
Abstract
Aim: to determine the prevalence of OHSS and clinical outcomes in high-risk
women undergoing ART following calcium IV infusion.
Methods: Double-blinded randomized controlled trial included two hundred women
at risk to develop OHSS undergoing IVF/ICSI treatment cycle subdivided randomly
into two equal groups; group I (intervention group (study/calcium infusion group,
n=100) received intravenous infusion of 10 mL 10% calcium gluconate in 100 mL
0.9% saline solution on the day of ovum pick-up (OPU) and days 1, 2, and 3 after,
and group II (control/placebo group, n=100) received 100 mL 0.9% saline solution
on the day of OPU and days 1, 2, and 3 after.
Main Outcome Measure: Incidence of OHSS.
Results: OHSS incidence was significantly lower in the calcium infusion group
(group I) than in the placebo group (group II): 8 (8%) vs. 26 (26%); moderate OHSS
was significantly lower in group I than in group II: 3 (3%) vs. 10 (10%); and severe
OHSS was significantly lower in group I than in group II: 0 vs. 4 (4%).
Conclusion: IV calcium infusion has a significant preventive role against OHSS
without adverse effect on pregnancy outcomes.